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Abstract
Background: Myocardial microvascular loss after myocardial infarction (MI) remains a therapeutic challenge. Autologous
stem cell therapy was considered as an alternative; however, it has shown modest benefits due to the impairing effects
of cardiovascular risk factors on stem cells. Allogenic adipose-derived stem cells (ASCs) may overcome such limitations,
and because of their low immunogenicity and paracrine potential may be good candidates for cell therapy. In the
present study we investigated the effects of allogenic ASCs and their released products on cardiac rarefaction post MI.
Methods: Pig subcutaneous adipose tissue ASCs were isolated, expanded and GFP-labeled. ASC angiogenic function
was assessed by the in-vivo chick chorioallantoic membrane (CAM) model. Pigs underwent MI induction and 7 days
after were randomized to receive: allogenic ASCs (intracoronary infusion); conditioned media (CM; intravenous infusion);
ASCs + CM; or PBS/placebo (control). Cardiac damage and function were monitored by 3-T cardiac magnetic resonance
imaging upon infusion (baseline CMR) and 1 and 3 weeks thereafter. We assessed in the myocardium: microvessel
density; angiogenic markers (CD105, CD31, TF, VEGFR2, VEGFR1, vWF, eNOS, CD62); collagen deposition; and reparative
fibrosis (TGFβ/TβRII/collagen). Differential proteomics of ASCs and CM was performed to characterize the ASC
protein signature.
Results: CAM indicated a significant ASC proangiogenic capacity. In pigs after MI, only PBS/placebo animals
displayed an impaired cardiac function 3 weeks after infusion (p < 0.05 vs baseline). Administration of ASCs + CM
significantly enhanced neovessel formation and favored cardiac repair post MI (p < 0.05 vs the other groups).
Molecular markers of angiogenesis were significantly upregulated both at transcriptional and protein levels (p < 0.05).
The in-silico bioinformatics analysis of the ASC and CM proteome (interactome) indicated activation of a coordinated
protein network involved in the formation of microvessels and the resolution of rarefaction.
Conclusion: Coadministration of allogenic ASCs and their CM synergistically contribute to the neovascularization of
the infarcted myocardium through a coordinated upregulation of the proangiogenic protein interactome.
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Background
Advances in pharmacological therapy and interventional
techniques have increased the rate of survival in patients
suffering from acute myocardial infarction (MI) [1]. Yet
the development of heart failure at a later time point
due to reduced perfusion, microvessel rarefaction, irrevers-
ible cardiomyocyte loss and consequent adverse cardiac re-
modeling has increased dramatically [2]. Implantation of
adult stem cells into the ischemic damaged myocardium
has been investigated for its potential to repair/regenerate
the injured cells within the infarct zone [3]. However, re-
cent systematic review and meta-analysis have evidenced
that administration of autologous stem cells exerts modest
and limited benefits in ischemic heart disease (IHD) pa-
tients [4]. The presence of cardiovascular risk factors and
metabolic disorders in cardiac patients seems to negatively
influence the effects of adult stem/progenitor stem cells,
discouraging their autologous use in the clinical setting [5].
In this regard, allogenic adipose-derived stem cells (ASCs)
from obese patients display an impaired angiogenic poten-
tial [6, 7] and clustering of risk factors has been shown to
reduce ASC and bone-marrow-derived cell pluripotency
and self-renewal [8–11]. The use of allogenic stem cells
from healthy donors may overcome these limitations.
In contrast to other adult stem cells, mesenchymal
stem cells (MSCs) have been demonstrated to have im-
munomodulatory and immunosuppressive properties
[12]. Moreover, MSCs are considered to be immunopri-
vileged due to lack of expression of class II major histo-
compatibility complex and costimulatory molecules on
the cell surface [13] and, consequently, allogeneic ad-
ministration of MSCs does not stimulate donor-specific
alloimmune reactions as shown in several clinical trials
[14, 15]. Emerging evidence supports that among all
MSCs those derived from the adipose tissue (i.e., ASCs)
hold great potential for allogenic use because, in addition
to their inherent and proven low immune reactivity
[16, 17], they are highly abundant, easily accessible and
expandable in culture. Administration of ASCs has so
far shown promising results across a wide range of
therapeutic applications including bone–cartilage de-
fects, inflammatory-based disease and IHD [18]. In this
latter regard, several animal studies seem to indicate
that administration of ASCs exerts cardiac beneficial ef-
fects as compared with the administration of placebo-
control media likely through paracrine/autocrine-related
mechanisms [16, 19]. Many experimental studies concur
that most of the benefits associated with the administra-
tion of ASCs are largely mediated by the actions of cyto-
kines and growth factors secreted by the ASCs rather than
by ASC transdifferentiation and engraftment [20–23].
Because microvessel rarefaction is a common pathogenic
landmark in the ischemic myocardium, here we sought to
determine in a pig model of MI using clinical standard
perioperative procedures (antiplatelet treatment) and ope-
rating blindly [24] whether coadministration of ASCs and
conditioned media (CM) could overcome myocardial
rarefaction and whether the effects were due to ASCs or
their secretome.
Methods
Materials and methods are expanded in Additional file 1.
Ethical approval
The experimental procedures with animals were reviewed
and approved by the Institutional Animal Care and
Use Committees (CEEA-ICCC) and authorized by the
Animal Experimental Committee of the local government
(# 5601) in accordance with Spanish law (RD 53/2013)
and European Directive 2010/63/EU.
Experimental design
Pigs (n = 20) were subjected to MI induction. One week
post MI, the animals were randomized to receive: ASCs
(1 × 107 cells); CM (30 ml); ASCs and their CM; or PBS
(control; 30 ml). ASC coronary delivery was performed
with an over-the-wire catheter and total balloon occlu-
sion for 2 min. CM was administered intravenously. Cell
preparations were administered blindly by the surgical
operators. Animals were then brought to the cardiac mag-
netic resonance imaging (CMR) facilities for baseline
CMR measurements (1 week post MI) and were followed-
up at 1 and 3 weeks thereafter (2 and 4 weeks post MI,
respectively) and then sacrificed.
ASC isolation, characterization and preparation for infusion
Subcutaneous adipose tissue was harvested from the neck
of healthy pigs and processed for ASC isolation and expan-
sion under hypoxic conditions [7]. The day before infusion,
the expanded ASCs were washed and serum-free medium
was added. After 24 h, the secretome of ASCs released to
the medium (CM) was collected, centrifuged and filtered.
Then 30 ml of sample was kept at 4 °C until infusion. ASCs
(1 × 107 cells) were resuspended in 2 ml PBS and kept at
4 °C until intracoronary administration. Previously, ASCs
had been characterized by cell surface marker expression
by flow cytometry and differentiation potential to mesen-
chymal cell lineages. Aliquots of ASCs and CM were kept
for proteomics.
In-vitro ASC function: proof-of-principle characterization
a) 3D cultures: ASC endothelial cell differentiation
was evaluated by capillary network formation with
HMEC-1 (microvascular endothelial cells) on
coculture in 3D matrigel plugs.
b) Chorioallantoic membrane assay (CAM)
immunofluorescence: fertilized chicken eggs
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were incubated for 3 days. A small opening was
then made in the shell, exposing the CAM. The
window was covered with cellophane tape and
the eggs were returned to the incubator. Six days
later, growth factor-reduced matrigel droplets
(containing 105 ASCs, 20 μl concentrated
CM (×10) or 105 ASCs + 20 μl concentrated CM)
were applied onto the CAM while placement
onto big pre-existing blood vessels was avoided.
Matrigel droplets containing 20 μl PBS served as
negative controls. Following 2 days of incubation
the eggs were opened and photographed, and the
CAM was carefully dissected and processed for
histological analysis against von Willebrand
factor (vWF).
c) Microvesicle release: ASC-GFP+ microvesicles
release into the CM were analyzed by flow
cytometry.
Experimental model of MI
MI was induced by 90-min total balloon occlusion of the
LAD as described previously [25]. All animals underwent
transthoracic echocardiography before inducing ischemia
and upon reperfusion to monitor the impact of MI induc-
tion on LVEF [26].
GFP-lentiviral transduction of ASCs: assessment of ASC
cardiac homing
We performed a substudy (n = 4 pigs) to confirm ASC
retention and homing within the infarcted region post
infusion. To that end, ASCs were transduced with GFP-
expressing lentiviral vectors and 1 × 107ASC-GFP+ cells
were intracoronary infused into MI-induced pigs. Animals
were sacrificed 24 h later and samples from multiple car-
diac regions (left and right ventricle, ischemic and remote
myocardium, atrium) and vascular beds (coronary arteries
and different aortic regions) were rapidly obtained for
GFP detection.
Cardiac magnetic resonance imaging
CMR analysis was performed serially as reported previously
[25] 1 week post MI just after ASC, CM, ASC+CM or
PBS infusion (baseline), 1 week post infusion (2 weeks
post MI) and 3 weeks post infusion (4 weeks post MI).
The following CMR sequences were acquired: “cine”
(b-SSFP) imaging sequence to assess wall motion and
cardiac function; and late gadolinium enhancement
(LGE) to assess the amount and extent of myocardial
necrosis. CMR images were analyzed using dedicated
software by a CMR-trained cardiologist blinded to the
study medication [27].
Assessment of myocardial vascular density and
angiogenesis
Neovessel formation was assessed by lectin staining and
via the analysis of angiogenic markers including gene
levels of CD105, vWF, endothelial nitric oxide synthase
(eNOS), vascular endothelial growth factor receptor type
2 (VEGFR2), VEGF1, CD31, CD62 and tissue factor (TF)
as well as protein activation and/or expression of eNOS
phosphorylated in Thr495, eNOS, CD105 and vWF.
Myocardial fibrosis
Myocardial fibrosis was assessed at a transcriptional
level (analysis of transforming growth factor beta recep-
tor (TGFβR), TGFβ, and collagen type I and type III)
and by histological Masson’s trichromic staining.
Proteomic analysis
Proteomic analysis was performed on ASCs and their
secretome (CM). For all proteomic analyses, protein ex-
tracts were separated by bidimensional gel electrophoresis
(2-DE) and protein spots of interest were identified by
matrix-assisted laser desorption/ionization–time of flight
(MALDI-TOF/TOF) as described previously [28].
In-silico bioinformatics analysis
The statistically significant functional networks in which
the identified proteins were involved were generated
through the use of ingenuity pathway analysis (IPA;
Ingenuity Systems, www.ingenuity.com). The functional
analysis of a network identified the biological function
and/or disease that were most significant to the mole-
cules in the network. The network molecules associated
with biological functions and/or diseases in the Ingenuity
Knowledge Base were considered for the analysis.
Statistical analysis
The Shapiro–Wilk test was applied to verify the normal
distribution of the data and statistical analysis was ap-
plied accordingly. Within the porcine studies, data were
analyzed by a nonparametric statistical analysis and re-
sults are reported as medians and interquartile range
(IQR). For independent factors (comparisons between
groups) we performed Mann–Whitney analysis; for re-
peated measurements, Wilcoxon and Friedman analyses
were appropriate. For the chicken egg analysis we ap-
plied a one-way ANOVA followed by Bonferroni’s mul-
tiple comparison test. Finally, for in-silico bioinformatics
analysis, a right‐tailed Fisher’s exact test was used to
calculate a p value determining the probability that each
biological function and/or disease assigned to that net-
work is due to chance alone.
All statistical tests conducted were two-sided and
p < 0.05 was considered significant. Statistical analyses
were performed with Statview.
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Results
ASC characterization
Flow cytometry demonstrated that cultured swine ASCs
were positive for surface markers characteristic of ASCs
including CD105 (99 ± 1%), CD29 (78 ± 4%) and CD90
(90 ± 3%) and negative for CD45 (1.2 ± 0.1%), thereby ex-
pressing the mesenchymal cell specific markers reported
by our group and others [6, 29]. ASC differentiation po-
tential to mesenchymal cell lineages was assessed. As
shown in Additional file 2, after 21 days of induction
with specific differentiation medium, staining for lipids
and calcium deposition confirmed the differentiation of
ASCs towards adipogenic and osteogenic lineages, re-
spectively. Finally, we performed a 3D coculture system
of ASCs with endothelial cells to further demonstrate
the capacity of ASCs to migrate, contact and localize
around the endothelial cells, providing support and stability
to the developed capillary-like structures (Fig. 1a, b).
Analysis of CM evidenced the presence of ASC-released
microvesicles, of which 30% were positive for both Annexin
V and GFP (Fig. 1c).
Chick CAM model of angiogenesis
As shown in Fig. 2, ASC + CM seeding in the scaffolds
induced a 2-fold and 4-fold increase in angiogenesis in
the border area between the CAM and the scaffolds as
compared with the ASCs or CM alone as detected by
vWF staining (p < 0.05). ASCs alone also induced an
angiogenic response that reached significance versus
control (p < 0.05) but was not as great as combined treat-
ment. CM seeding did not induce CAM angiogenesis.
ASC homing
As observed in Additional file 3A, GFP was detected by
RT-PCR in the LAD and in the layers of the ischemic
damaged myocardium (from endocardium to epicar-
dium) at 24 h post delivery of ASCs. In contrast, it was
undetectable in the remote myocardium, circumflex
and right coronary artery, atria, right ventricle and the
aorta. Confocal microscopy analysis revealed the
presence of GFP+ cells in the LAD and in the ischemic
cardiac tissue (Additional file 3B). GFP+ cells were not
detected in the nonischemic myocardium (image not
shown).
Cardiac function and damage
Echocardiography revealed that all animals showed a
comparable impairment in the left ventricle ejection
fraction (LVEF; average 29 (27–30)% decrease) after 90 min
of complete coronary ischemia (p < 0.05 vs prior MI). Simi-
larly, no variations were detected in hemodynamic parame-
ters (heart rate and mean blood pressure) during MI
induction among all groups (average: 76 (74–76) bpm and
56 (54–56) mmHg, respectively).
Fig. 1 ASC characterization. a. ASCs (green) and endothelial cells (red) in a 3D basement membrane coculture system for 24 h. b. Magnification to
visualize ASC incorporation (white arrowhead) within the capillary network. c. Flow cytometry analysis of microvesicles contained in the CM.
Ann Annexin V, GFP green fluorescent protein
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CMR analysis at 1 week post MI (baseline) showed
that all groups displayed a comparable deterioration in
LVEF and size of infarction. At this time point allogenic
cell preparations were administered by coronary infusion
of placebo solution or ASCs and intravenous injection of
placebo or CM (Table 1). Follow-up CMR analysis showed
a deterioration in cardiac contractility in control animals
3 weeks post infusion as compared with baseline, with a
marked impairment in left ventricular end-diastolic vol-
ume (LVEDV; 38.2% worse), left ventricular end-systolic
volume (LVESV; 19.2% worse) and LVEF (4.8% worse) vs
the other groups (p < 0.05; Fig. 3a, b). Such cardiac deteri-
oration was not detected in those animals administered
CM, ASCs or ASCs + CM in which cardiac performance
remained unchanged as compared with baseline (Table 1).
No differences were detected in the size of the scar at
3 weeks post infusion among the different animal groups
(Additional file 4A). Histopathological analysis of the scar
by triphenyl tetrazolium chloride (TTC) staining showed
reparative fibrosis by increase collagen in the scar area
Fig. 2 Chick CAM model of angiogenesis. a Immunohistochemical (IHC) score for vWF staining. Each sample was analyzed double blind and
independently by two investigators. Staining (brown) was semiquantitatively scored as 0, 1, 2 or 3 for absence, weak, moderate and strong staining,
respectively. b–e Representative macroscopic pictures of 48-h incubated matrigel scaffolds in the in-vivo CAM assay. f–i Representative immunochemical
staining of vWF in sections of matrigel–CAM junction. *p < 0.05 vs PBS, CM and ASCs; †p < 0.05 vs PBS. ASC adipose-derived mesenchymal stem cell, CM
conditioned media, PBS phosphate-buffered saline
Table 1 MRI analysis of cardiac performance and scar size
Baseline
(1 week post MI)
1 week post infusion
(2 weeks post MI)
3 weeks post infusion
(4 weeks post MI)
LVEF (%) PBS 48.4 (48.3–50.1) 48.9 (46.6–50.7) 46.5 (46.3–48.1)*
ASCs 47.7 (47.6–54.2) 48.3 (47.5–54.1) 48.7 (47.1–49.7)
CM 47.2 (46.5–47.5) 48.2 (48.0–49.4) 49.5 (48.2–52.1)
ASCs + CM 50.0 (46.4–53.0) 49.5 (48.7–51.0) 47.6 (47.3–49.6)
LVEDV (ml) PBS 91.9 (85.3–94.1) 107.5 (101.0–109.1)* 118.7 (115.0–125.7)*†
ASCs 113.0 (105.0–116.0) 123.2 (101.3–124.3) 121.0 (117.3–129.3)
CM 87.7(81.9–122.8) 93.4 (89.0–94.1)* 119.2 (106.1–122.3)
ASCs + CM 91.4 (89.0–98.4) 93.7 (84.0–124.4) 136.32 (82.1–153.0)
LVESV (ml) PBS 44.0 (40.0–46.2) 55.2 (46.1–58.3) 63.4 (45.0–65.2)†
ASCs 55.0 (49.9–60.7) 64.4 (51.4–64.9) 62.3 (60.6–66.0)
CM 42.9 (40.9–64.8) 47.2 (46.0–49.4) 60.2 (47.5–61.5)
ASCs + CM 46.1 (40.4–50.3) 48.0 (42.0–49.5) 64.8 (43.3–77.0)
Scar size (g) PBS 11.6 (10.5–12.4) 10.8 (10.1–13.2) 10.4 (9.8–11.7)
ASCs 9.9 (9.0–16.1) 9.5 (9.4–13.9) 10.8 (9.6–14.4)
CM 11.3 (9.7–13.2) 10.1 (9.2–11.0) 9.5 (8.1–9.9)
ASCs + CM 13.0 (10.0–15.0) 12.3 (10.2–14.0) 10.8 (7.2–11.5)
ASC adipose-derived stem cell, CM ASC conditioned media. LVEF left ventricular ejection fraction, LVEDV left ventricular end-diastolic volume, LVESV left ventricular
end-systolic volume, MI myocardial infarction, MRI magnetic resonance imaging, PBS phosphate-buffered saline
*p < 0.05 vs baseline
†p < 0.05 vs time
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which highly correlated with the CMR data (r = 0.85;
p < 0.01; Additional file 4B).
Vessel density
Total vessel density measured by histology operators
was found enhanced by 40% in the ischemic myocar-
dium of animals that received the combination of ASCs
and CM as compared with ASCs or CM alone or
placebo-control (p < 0.05; Fig. 4). The amount of vessels
detected in the infarcted area of ASC + CM animals was
comparable with that observed on the remote nonis-
chemic myocardium.
Markers of neovessel formation
We next determined myocardial gene and protein ex-
pression of markers involved in new vessel formation.
CD105 (Fig. 5a) and vWF (Fig. 5b) gene expression and
protein levels were significantly higher in the ischemic
myocardium of those animals administered ASCs + CM
as compared with ASCs or CM alone and PBS control
(p < 0.05). Moreover, not only eNOS transcription levels
but also eNOS activity was markedly enhanced within
the ischemic myocardium of animals administered
ASCs + CM (p < 0.05 vs the other three groups; Fig. 5c).
Consistent with these observations, transcription of
VEGFR2, TF, CD62 and CD31 was also found to be sig-
nificantly increased in those animals receiving ASCs +
CM (Fig. 6), further supporting, at a molecular level, a
proangiogenic synergistic effect of ASC and ASC relea-
sate (CM) administration. VEGF1 was found to be up-
regulated by ASCs + CM and ASCs (Fig. 6).
Reparative fibrosis
Gene expression of TGFβR/TGFβ/collagen type III (Fig. 7a)
and collagen deposition (Fig. 7b) was found to be upregu-
lated in the evolving scar of animals administered ASCs as
Fig. 3 Cardiac function analysis. Changes in cardiac volumes (a) and
contractility (b) 3 weeks post PBS, CM, ASC or CM+ASC administration
expressed as relative percentage change vs post infusion. ASC adipose-
derived stem cell, CM ASC conditioned media, LVEF left ventricular ejec-
tion fraction, LVEDV left ventricular end-diastolic volume, LVESV left ven-
tricular end-systolic volume, MI myocardial infarction
Fig. 4 Vessel density analysis of the ischemic and nonischemic myocardium assessed by lectin staining and representative images of the ischemic
cardiac tissue. *p < 0.05 vs ASCs, ASC releasate and PBS within the ischemic cardiac tissue. ASC adipose-derived stem cell, CM ASC conditioned media,
PBS phosphate-buffered saline
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Fig. 5 Molecular analysis (gene and protein expression) of markers involved in neovessel formation within the cardiac tissue: a CD105, b von
Willebrand factor (vWF) and c endothelial nitric oxide synthase (eNOS). *p < 0.05 vs ASC, CM and PBS within the ischemic cardiac tissue; †p < 0.05
vs PBS within the ischemic myocardium. ASC adipose-derived stem cell, CM ASC conditioned media, PBS phosphate-buffered saline
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compared with animals administered PBS and CM
(p < 0.05). This effect was further enhanced in animals
coadministered ASCs + CM (p < 0.05 vs ASCs alone).
Fibrosis was barely detectable in the nonischemic myocar-
dium (Fig. 7a).
ASC-related proteome
In order to elucidate the potential mediators by which
coadministration of ASCs and CM enhance neovessel
formation we analyzed the ASC-related proteome, which
included the ASC secretome (CM) and the ASC proteome
(ASC cytosol and membrane fractions).
a) ASC secretome analysis: we performed a comparative
proteomic approach between CM and cell-free culture
medium (negative control). Fetuin alpha-1 antitrypsin,
ApoA-I, serum albumin and serotransferrin were
identified in both CM and cell-free culture medium
and therefore their presence was attributed to the
culture medium (Fig. 8a). As expected, GFP was solely
identified in the secretome of ASCs and its detection
supported its extracellular release.
Figure 8b depicts the proteins released by ASCs into
the media during cell culture (ASC secretome). As
shown in Additional file 5, we identified proteins related
to five functional categories with potential paracrine
properties within the CM. These functional groups were
related to angiogenesis, cell proliferation/differentiation/
apoptosis regulation, protein processing/chaperone ac-
tivity and structural proteins.
b) ASC proteome analysis: we further analyzed ASC
cytosolic and membrane fractions (Fig. 9). Proteins
identified in the ASC proteome (Additional file 5)
were related to 11 different functional categories:
angiogenesis, antioxidant/redox homeostasis, cell
proliferation/differentiation/apoptosis regulation,
coagulation/hemostasis, defense response,
metabolism, protein processing/chaperone activity,
proteolysis, signaling/gene transcription, structural
and transport/trafficking proteins.
c) ASC interactome: we analyzed the functional groups
of proteins identified in both fractions (CM and
ASCs; Additional file 5) in order to determine the
potential interactions (i.e., interactome) behind the
synergistic effect observed upon ASC + CM
administration. Table 2 presents the functional
groups of the proteins identified in the ASC-related
proteome. We observe that structural proteins are
found in both the ASC secretome and the ASC
proteome, although with a differential protein
contribution of each fraction. Additionally, the ASC
secretome mainly contained proteins related to
angiogenesis and cell proliferation/differentiation/
apoptosis regulation whereas the ASC proteome was
mostly represented by proteins involved in protein
processing regulation and chaperone activity.
Fig. 6 Myocardial gene expression of several markers involved in new vessel formation. VEGFR2 vascular endothelial growth factor receptor 2, TF
tissue factor, CD62 P-selectin, CD31 platelet. *p < 0.05 vs ASCs, CM and PBS within the ischemic cardiac tissue; †p < 0.05 vs CM and PBS within the
ischemic cardiac tissue. ASC adipose-derived stem cell, CM ASC conditioned media, PBS phosphate-buffered saline
Vilahur et al. Stem Cell Research & Therapy  (2017) 8:52 Page 8 of 15
We further analyzed the functional networks in which
the proteins identified in the ASC interactome were in-
volved by performing an in-silico bioinformatic analysis
using the IPA software. This analysis revealed that the
most representative network in the ASC interactome
was related to blood vessel development and neovascu-
larization (Additional file 6).
Discussion
Common risk factors associated with coronary artery
disease have been shown to attenuate the functional ac-
tivity of progenitor/adult stem cells likely restricting the
effectiveness of autologous cell-based therapy. Therefore,
delivery of allogenic stem cells with very low immuno-
genic reactivity may become a therapeutic option to
Fig. 7 Transcript levels of fibrotic markers (a) and collagen deposition in the ischemic myocardium assessed by Masson’s trichromic staining (b).
*p < 0.05 vs all; †p < 0.05 vs CM and PBS within the ischemic cardiac tissue. ASC adipose-derived stem cell, CM ASC conditioned media, PBS
phosphate-buffered saline
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Fig. 8 Comparative proteomic analysis between CM and cell-free culture medium. CM conditioned media a. Fetuin alpha-1 antitrypsin, ApoA-I,
and serum albumin and serotransferrin identification. b. Proteins released by ASCs into the media during cell culture [ASC secretome or condi-
tioned media (CM)]
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enhance stem cell potential. Among all kind of stem
cells, MSCs and, particularly, ASCs exert considerable
immunomodulatory properties and exhibit a low im-
munogenic profile [16]. ASCs have so far demonstrated
encouraging data in several preclinical studies and have
proven safety in phase I and phase IIb clinical trials
[30, 31]. Autologous ASC therapeutic potential is mainly
explained by the production of bioactive molecules that
mediate neovascularization, cell survival and proliferation
[32]. Yet little is known about the mediators involved and
their mechanisms of action. Moreover, key questions re-
main on the best cell-based preparation, delivery method,
dosage and timing. In this study we demonstrate, by im-
munohistochemical and molecular approaches, that both
ASCs and their secretome have beneficial effects. Intra-
venous administration of CM with an intracoronary
infusion of ASCs enhances neovessel formation in the is-
chemic myocardium as compared with the delivery of CM
or ASCs alone. We also identify, by proteomic approaches,
the protein networks that may potentially contribute to
the detected proangiogenic synergistic effect. Finally, we
provide evidence of a positive synergistic effect between
ASCs and CM over the evolving reparative scar.
Despite relative enthusiasm arising from rodent data,
application of MSC therapy has shown limited clinical
benefits in the setting of MI. Concerning ASCs, some
preclinical studies have reported a slight amelioration in
cardiac contractility [32, 33] whereas others have
shown no changes in LVEF at 4 weeks post administra-
tion [16, 34]. Recent data from the APOLLO and the
PRECISE trials (phase I/IIb trials) suggest that admin-
istration of ASCs preserves cardiac function [30, 31].
In our study LVEF is preserved in those animals that re-
ceived intravenous CM and/or intracoronary ASCs 3 weeks
post infusion in contrast to placebo-control animals whose
Fig. 9 Proteomic analysis of ASC membrane fraction and ASC cytosolic fraction. ASC adipose-derived stem cell
Table 2 Functional groups in the ASC interactome and the
percentage of identified proteins
Functional group in donor cell CM (%) ASC (%)
Angiogenesis 17 5





Defense response 0 1
Metabolism 0 3
Protein processing/chaperone 6 22
Proteolysis 0 3
Signaling/gene transcription 0 14
Structural 50 26
Transport/trafficking 0 8
ASC adipose-derived stem cell, CM conditioned media
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cardiac contractility is found to be significantly deterio-
rated. Moreover, end-systolic and end-diastolic volumes
are worse in PBS-control animals as compared with
animals administered ASCs or CM, suggesting ASC-
related benefits in cardiac contractility and remodeling.
Interestingly, results from the present study reveal that
a single intravenous delivery of CM obtained from
ASCs (1 × 107 cells) exerts similar protective effects to
that of ASCs in cardiac performance (CMR detected
parameters) but not in the recovery of the rarefaction
(loss of microvessels) where the effect is improved by
ASCs plus secretome administration. Administration of
stem cells capable of directly inducing vessel formation
or secreting proangiogenic factors holds great promise
to repair the ischemic damaged tissue. The ability of
ASCs to promote angiogenesis has been assessed in
multiple preclinical MI experimental animal models
[16, 17, 19]. In fact, evidence indicates that ASCs have
higher angiogenic capacities than bone marrow MSCs
[35, 36]. Several reports have suggested that ASCs in-
crease vascularity by differentiation into pericytes (cells
capable of stabilizing the microvasculature) both in vitro
and in vitro [37, 38] but ASC transdifferentiation into the
endothelial cell lineage has not been shown [22, 23, 34],
attributing their angiogenic potential to a paracrine
activity [17]. We demonstrate through two different in-
vivo models that a combination of CM plus ASCs sig-
nificantly enhances neoangiogenesis as compared with
CM or ASCs alone, suggesting a synergistic interaction
among ASCs and CM. Indeed, we detect in the ischemic
myocardium a significant increase in both microvessel
density and the expression of different angiogenic markers.
As such, mRNA transcripts and protein levels reveal that,
as compared with animals administered ASCs, CM or PBS,
pigs treated with ASCs + CM express: a higher amount of
VEGFR2 (the receptor of one of the most potent in-
ducers of angiogenesis, VEGF); specific inducers and
markers of active neovessel formation (TF and CD105,
respectively) [39]; and a higher number of endothelial
cells (P-eNOS, vWF, CD31, CD62) in the ischemic cardiac
tissue. Interestingly, however, our results also highlight the
ability of ASCs alone to enhance VEGF expression, an ef-
fect not observed in CM-alone administered animals.
These data indicate a differential contribution of ASCs
and CM to neovessel formation, as further discussed in
the following.
The increased vascular density and molecular expres-
sion of active neoangiogenic/vascular factors detected
when combining ASCs and CM at 3 weeks may translate
into the amelioration of cardiac contractility in a longer-
follow-up period, as seen at 3 months post infusion with
autologous cells [19]. Of note, the limited size of infarc-
tion with the concomitant mild reduction in ejection frac-
tion may have underestimated the acute potential benefits
afforded by ASC + CM administration. Further studies are
required to determine the effects of ASCs + CM on LVEF
and cardiac remodeling upon a more severe ischemic in-
sult and after longer survival periods.
No consensus exists as per the optimal timing of stem
cell administration. We choose a 7-day delay between
acute MI and ASC/CM administration based on the
following considerations: to closely match clinical trial
protocols [40]; to limit interactions with the “cardiac
niche effect” favored by MI (progenitor cell recruitment);
and to avoid further acute cardiac damage due to ASC-
related coronary plugging [41]. In this respect, intracor-
onary administration of 1 × 107 ADSCs in pigs has been
shown to induce the no-reflow phenomenon [32] as well
as to compromise coronary microcirculation [42]. These
observations support the coadministration, by peripheral
delivery, of soluble secreted molecules to increase the
benefit of ASC therapy, avoiding the risks and detrimen-
tal effects associated with the intracoronary infusion of
very high amounts of ASCs.
A recent study in pigs, however, has reported that neo-
vascularization is found to be enhanced when ASCs are
given early after reperfusion as compared with 1 week
later, likely through paracrine effects [16]. Based on our
findings which demonstrate a significant enhanced neo-
vascularization when combining ASCs plus CM and
taking into consideration that ASC preconditioning with
low oxygen levels induces a faster growth and enhances
ASC and CM angiogenic potential [7], the effect of
administering ASCs + CM early after revascularization
deserves to be investigated.
The complementary proangiogenic effects detected in
the ischemic myocardium after the coadministration of
ASCs and CM drove the investigation by proteomic ap-
proaches of the potential effector molecules. We have
identified the presence of angiogenic and inducers of cell
proliferation/differentiation in the ASC secretome. Most
interestingly, we have identified different and complemen-
tary angiogenic proteins in ASCs and CM, supporting the
concept of a combined superior effect of ASCs plus CM.
The same occurs for proteins related to cell prolifera-
tion and differentiation which are critically involved in
neovessel formation. As such, annexin A1, a protein
known to mediate VEGF-induced endothelial cell mi-
gration by regulating the formation of lamellipodia [43],
is only detected in the cytosolic ASC-related fraction
whereas peroxiredoxin-1, a protein known to stimulate
endothelial cell proliferation and migration by interact-
ing with toll-like receptor 4 (TLR4), is only identified in
the ASC secretome [44]. Finally, in contrast to the
ASC-related secretome, ASCs provide a high number
of proteins implicated in the regulation of protein
translation and folding, and with molecular chaperone
activity such as heat shock protein (HSP)70-1A and
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protein disulfide isomerase (PDI) known to be involved
in-vivo angiogenesis [45, 46]. Overall, our observations
suggest the existence of a synergistic and coordinated pro-
tein network in the ASC interactome involved in angio-
genesis modulation. Further confirming this hypothesis,
in-silico bioinformatic analysis of the ASC interactome
clearly shows a key role for ASC-related proteins in angio-
genesis (Additional file 6).
Besides angiogenesis, ASCs have been shown to exert
anti-inflammatory and anti-apoptotic properties even-
tually favoring the cardiac healing process [20]. Cardiac
repair is ultimately characterized by fibrous tissue de-
position at the site of cardiomyocyte loss in order to
preserve structural integrity and prevent myocardial
rupture (reparative fibrosis), particularly in transmural
infarcts such as the ones performed in the present
study. This process requires a series of coordinated mo-
lecular and cellular events in which the TGFβ/TβRII
signaling governs myofibroblast-related collagen deposition
[47]. We show that administration of ASCs favors TGFβ/
TβRII-related collagen synthesis in the evolving scar,
helping to maintain myocardial shape and structure.
Interestingly, this effect is found to be enhanced when
combining ASCs plus CM, further supporting a synergistic
cross-talk between ASCs and their secretome and in line
with the proteomic-related functional groups. Indeed, we
observe that ASCs secrete multiple structural proteins such
as vimentin, tropomyosin and actin which may have con-
tributed to cellular assembly favoring the healing repair
process. This was confirmed by in-silico bioinformatic ana-
lysis that revealed the implication of several structural pro-
teins together with antiapoptotic and prosurvival effectors
in the cellular assembly and organization functional net-
work. Importantly, neither ASCs nor CM induced intersti-
tial reactive fibrosis (i.e., deleterious collagen deposition in
nonischemic cardiac tissue leading to adverse cardiac re-
modeling), in agreement with recent observations in in-
farcted mice transplanted a construct of multilayered ASC
sheets [48].
Conclusion
Peripheral vein administration of ASC paracrine media-
tors in combination with local coronary delivery of
ASCs synergistically contributes to enhance the neovas-
cularization of the infarcted myocardium through
multiple effectors that interact through a complemen-
tary and coordinated protein network. Further studies
should approach the evaluation of effects at periods
longer than 3 weeks. In addition, further studies are
needed to ascertain which of the released molecules are
endowed with beneficial effects in order to improve de-
livery of purified paracrine regulators of angiogenesis
and neovessel formation.
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Additional file 1: Is a Word file presenting supplemental materials and
methods. (DOC 84 kb)
Additional file 2: Is a figure showing adipogenic and osteogenic
differentiation of ASCs. ASC-related differentiation towards mesodermal
lineages was determined by specific staining; Alizarin red staining showed
extracellular calcium deposition after osteogenic differentiation whereas
adipogenic differentiation was evidenced by lipid droplets stained by Oil
red. (TIF 8942 kb)
Additional file 3: Is a table and figure showing analysis of ASC homing.
(A) GFP+ detection in different regions of the heart and aorta by real-time
PCR analysis. We set a cycle threshold (CT) of 28 as the cutoff value.
(B) ASC-GFP+ cells by confocal analysis in the left anterior descending
coronary artery and ischemic left ventricle (red: smooth muscle actin;
green: GFP; blue: nuclei). Identification was carried out 24 h after intracoronary
infusion of ASC-GFP+ cells to the infarcted myocardium. LAD left anterior
descending coronary artery, LV left ventricle. (TIF 5200 kb)
Additional file 4: Is a figure showing correlation between infarct size
assessment by histopathology and by CMR in all animals of the study.
CM adipose-derived stem cell (ASC) conditioned media. (TIF 2419 kb)
Additional file 5: Is Table S1 presenting identified proteins by MALDI-TOF/
TOF in ASCs and CM (ASC releasate). (DOC 171 kb)
Additional file 6: Is a figure showing the ASC interactome–angiogenesis
network. (TIF 11036 kb)
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